VG-2025

N/A

Report date: 2026/04/14 20:00:15

Base Information

Drug NameVG-2025
Drug Alias NameVG-2025
ClassificationCell and gene therapy > Gene therapyBiologics > Oncolytic virus
Mechanisms of ActionCell death stimulantsImmunologic cytotoxicity
TargetsUpdating
Therapy Area/IndicationsSolid tumoursCholangiocarcinomaCarcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesViroGin Biotech Ltd
China Registration ClassN/A

Develop Information

Active CompaniesVirogin Biotech Canada LtdShanghai Funuojian Biotechnology Co LtdViroGin Biotech Ltd +[4] 
Inactive CompaniesThe University Of Texas MD Anderson Cancer Center
Active IndicationsSolid tumoursCholangiocarcinoma
Inactive IndicationsCarcinoma

Other Information

ATC CodeN/A
Related LinksN/A